Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
23andMe Holding ( (MEHCQ) ) just unveiled an update.
On March 23, 2025, Chrome Holding Co. and its subsidiaries filed for Chapter 11 bankruptcy in the United States Bankruptcy Court for the Eastern District of Missouri. Subsequently, on July 14, 2025, they sold most of their assets to 23andMe Research Institute for $302.5 million in cash. However, the Lemonaid telehealth business remained with the Debtors. Later, a higher offer for Lemonaid Health was received from Bambumeta Ventures, leading to a stock purchase agreement on September 10, 2025, for $10 million. The completion of this sale is subject to customary conditions, including court approval and regulatory clearances.
The most recent analyst rating on (MEHCQ) stock is a Hold with a $8.40 price target. To see the full list of analyst forecasts on 23andMe Holding stock, see the MEHCQ Stock Forecast page.
Spark’s Take on MEHCQ Stock
According to Spark, TipRanks’ AI Analyst, MEHCQ is a Neutral.
23andMe Holding’s overall stock performance is weak, primarily due to significant financial challenges, including declining revenues and persistent net losses. The technical analysis also suggests a bearish trend with no strong momentum to reverse it. The negative valuation metrics further highlight the company’s struggles with profitability. Improvements in financial performance and strategic adjustments to reverse negative trends are critical for enhancing investor confidence.
To see Spark’s full report on MEHCQ stock, click here.
More about 23andMe Holding
Average Trading Volume: 113,908
Technical Sentiment Signal: Sell
Current Market Cap: $108.2M
For detailed information about MEHCQ stock, go to TipRanks’ Stock Analysis page.